Document:

Document

Exhibit 10.1

CERTAIN Information Identified by “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

CONSULTING AGREEMENT

THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into as of May 18, 2020, effective as of May 11, 2020 (“Effective Date”), by and between Myovant Sciences GmbH (“Myovant”) having a registered office at Viaduktstrasse 8, 4051 Basel, Switzerland and Sumitovant Biopharma, INC. (“Sumitovant”), having an office at 151 W. 42nd Street, 15th Floor, New York NY 10036 (“Consultant”).

W I T N E S S E T H:

WHEREAS, Sumitovant Biopharma Ltd., an affiliate and beneficial owner of Consultant is the majority shareholder of Myovant Sciences Ltd. (“MSL”), Myovant’s affiliate and beneficial owner;

WHEREAS, Myovant desires to engage Consultant to provide services to Myovant, and Consultant desires to accept engagement on the terms and conditions hereinafter stated;

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, the parties agree as follows:

1.Services.

1.1.Consultant shall provide the services set forth on Exhibit A (the “Services”).  Adele Gulfo, Consultant’s Chief Business and Commercial Development Officer and a member of MSL’s Board of Directors, shall provide the Services to Myovant on behalf of Consultant under this Agreement (“Individual Consultant”).  

1.2.Consultant and Myovant acknowledge and agree that this Agreement is an independent contractor agreement and that Consultant is an independent contractor and that neither Consultant nor Individual Consultant is an agent or employee of Myovant.  Myovant shall have no withholding obligations with respect to Consultant’s or Individual Consultant’s compensation and Consultant shall be solely responsible for payment of, and shall indemnify and hold Myovant harmless against, all taxes, including, without limitation, federal, state and local taxes arising out of Consultant’s compensation under this Agreement and Individual Consultant’s compensation from Consultant.  With respect to the Services, Consultant and Individual Consultant shall not be covered by or have any rights to participate under any employee benefit plans of Myovant that are in existence or hereafter adopted or implemented and Myovant shall not be responsible for payment of workers’ compensation, disability benefits or unemployment insurance.  As an independent contractor, Consultant shall not have the power or authority to bind Myovant to any obligations whatsoever to third parties without the prior consent of Myovant. 

1.3.Consultant represents and warrants to Myovant that this Agreement does not violate or breach, and Consultant’s performance of Consultant’s obligations hereunder will not violate or breach, any terms or provisions of any agreement or understanding to which Consultant is subject or bound.  Consultant represents, warrants, covenants and agrees that it will not, during engagement by Myovant, improperly use or disclose any proprietary information or trade secrets of any other party, and will not share with Myovant any unpublished documents or any property belonging to any other party unless consented to in writing by said party.

1.4.Consultant represents and warrants that Consultant has not been debarred or received notice of any action or threat with respect to debarment under the provisions of the Generic Drug Enforcement Act of 1992, 21 U.S.C. § 335(a) or any similar legislation applicable in the US or in any other 

country where Myovant intends to develop its activities.  Consultant agrees to promptly notify Myovant upon receipt of any such notice or similar notice and further agrees, upon Myovant’s request, to provide a separate written certification, on a form provided by Myovant, to this effect.

2.Term of Engagement.

2.1.Subject to the terms and provisions set forth below in this Section 2, the term of Consultant’s engagement will begin on May 11, 2020 and continue through November11, 2020 or such earlier time as Myovant hires a permanent Chief Commercial Officer.  The Agreement may be renewed upon the mutual written consent of the parties.  

2.2.Either Myovant or Consultant may terminate the engagement of Consultant under this Agreement at any time for any reason by giving not less than fifteen (15) days prior written notice thereof to the other party.  

2.3.Upon termination of engagement pursuant to this Section 2, all obligations of Myovant under this Agreement shall terminate except with respect to payment for Services rendered prior to the date of termination, and reimbursement of expenses to which Consultant would have been entitled under this Agreement, it being agreed that such payment shall constitute full settlement of any and all claims of Consultant of every description. All of Consultant’s obligations, including without limitation the provisions of this agreement relating to Confidential Information, Trade Secrets and Other Confidential Information under this Agreement shall survive any termination of this Agreement in accordance with its terms.    

2.4.Consultant will, and will cause Individual Consultant to, provide Services hereunder in compliance with: 1) all applicable federal, state, and local laws and regulations including but not limited to the Federal Healthcare Programs Antikickback Statute and the Federal Food, Drug and Cosmetic Act; 2) the generally accepted standards of Consultant’s profession; 3) relevant industry guidelines and codes of ethics to the extent that they are applicable to the Services hereunder, including the Pharmaceutical Research and Manufacturers of America’s Code on Interactions With Health Care Professionals and 4) all of Consultant’s policies and procedures, including any disclosure/transparency obligations regarding fees obtained for consultancy services.

3.Compensation.

3.1. In consideration of the Services provided by Consultant, Myovant shall provide Consultant with $[***]/hour (the “Fee”) not to exceed a total of $120,000 without prior written approval of Myovant.  

3.2.All payments under this Agreement are contingent upon Consultant’s completion, execution and sending to Myovant a completed Form W-9, Form W-8-BEN or other foreign withholding certificate, as applicable.

3.3.Consultant shall submit a detailed, itemized invoice for Services to Myovant on a monthly basis, and Myovant shall remit payment for properly performed Services within forty-five (45) days of receipt of the invoice and all supporting documentation.  

3.4.Myovant and Consultant acknowledge and agree that the compensation herein represents the fair market value for the Services, is not influenced by the corporate relationship between Myovant and Consultant and has not been determined in a manner that takes into account the volume or value of any other business between Consultant and Myovant or any Myovant affiliate.  Under no circumstance shall Consultant be entitled to receive any compensation or consideration beyond the Fee, as a result of or in connection with this Agreement or the Services or in connection with any Invention.

3.5.Myovant and Consultant acknowledge and agree that this Agreement is a “Related Person Transaction” pursuant to MSL’s Related Person Transaction Policy and that MSL’s board Audit Committee must approve this Agreement before it becomes effective. Consultant acknowledges that MSL is a public company listed on the New York Stock Exchange and agrees and acknowledges that Myovant may have reporting obligations under the securities laws and regulations applicable to US listed entities with respect to this Agreement and any compensation paid to Consultant.

4.Expense Reimbursements.

Consultant shall be reimbursed for all reasonable and necessary expenses incurred by Consultant when travel is undertaken at Myovant’s request.  Prior to receiving such reimbursement, Consultant shall submit documentation and receipts for such expenses in excess of $25.00 in sufficient detail for deduction by Myovant as an expense.  

5.Confidential Information, Trade Secrets and Nonuse.

Myovant and Consultant acknowledge and agree that they have entered into a Nondisclosure and Common Interest Agreement (“NDA”) as of April 8, 2020 and that the provisions in the NDA related to confidentiality, trade secrets and nonuse shall apply to this Agreement.

6.Inventions.

6.1.Disclosure of Inventions.  Consultant shall promptly and fully disclose to Myovant any and all ideas, improvements, inventions, know-how, techniques and works of authorship learned, conceived or developed by Consultant or Individual Consultant pursuant to their performance of the Services for Myovant or of tasks assigned to them by Myovant hereunder (the “Service Product”).  Consultant agrees to keep and maintain reasonable, adequate and current records (in the form of notes, sketches, drawings or in any other form that may be required by Myovant) of all Service Product, and such records, subject to any prior rights thereto held by Consultant shall be available to and remain the sole property of Myovant at all times.

6.2.Inventions Assigned to Myovant.  Consultant agrees that, subject to any prior rights thereto held by Consultant, any and all Service Product shall be the sole and exclusive property of Myovant.  Consultant hereby assigns to Myovant all its right, title and interest in and to any and all Service Product.  Consultant explicitly acknowledges and agrees that all works of authorship contained in the Service Product are “works for hire” under the copyright laws of the United States, and that Myovant shall own the copyright in all such works of authorship.

6.3.Consultant further agrees that, except for any prior rights held by Consultant, Myovant is and shall be vested with all rights, title and interests, including patent, copyright, trade secret and trademark rights, in all of Consultant’s Service Product under this Agreement. Notwithstanding anything in this Agreement to the contrary, nothing in this Agreement restricts or otherwise deprives Consultant of any of its rights or proprietary interests in any materials or intellectual property that existed prior to and independent of performance of any of the Services (“Pre-Existing Materials”). If Pre-Existing Materials are delivered in connection with or as part of the Service Product, Consultant hereby grants Myovant a non-exclusive, worldwide license to use, duplicate modify, sublicense, distribute, display and otherwise exploit such Pre-Existing Materials, but in each case, solely to enable Myovant to use and benefit from the Service Product.

6.4.Obtaining Intellectual Property Protection.  Consultant agrees to assist Myovant in every proper way to obtain and enforce United States and foreign proprietary rights relating to the Service Product in any and all countries.  To that end, Consultant agrees to execute, verify and deliver such documents and perform such other acts (including appearing as a witness) as Myovant may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such proprietary rights and the assignment thereof.  In addition, Consultant agrees to 

execute, verify and deliver assignments of such proprietary rights in the Service Product to Myovant or its designee.  Consultant’s obligation to assist Myovant with respect to such proprietary rights in the Service Products in any and all countries shall continue beyond the termination of its engagement, but Myovant shall compensate Consultant at a reasonable rate after such termination for the time actually spent by Consultant at Myovant’s request on such assistance.

6.5.In the event Myovant is unable for any reason, after reasonable effort, to secure Consultant’s signature on any document needed in connection with the actions specified in the preceding paragraph, Consultant hereby irrevocably designates and appoints Myovant and its duly authorized officers and agents as his agent and attorney in fact, to act for and on it behalf to execute, verify and file, with the same legal force and effect as if executed by him, any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph.  Consultant hereby waives and quitclaims to Myovant any and all claims of any nature whatsoever which Consultant now or may hereafter have for infringement of any proprietary rights assigned to Myovant in accordance with this Section 6

7.Remedies and Special Severability.

7.1.Consultant acknowledges and agrees that by virtue of the duties and responsibilities attendant to Consultant’s engagement by Myovant and the special knowledge of Myovant’s affairs, business, clients, and operations, that Consultant will have as a consequence of such engagement, Myovant will suffer irreparable loss and damage if Consultant should breach or violate any of the covenants and agreements contained in Sections 5, and/or 6 hereof.  Consultant further acknowledges and agrees that each of such covenants is reasonably necessary to protect and preserve the business and the assets of Myovant.  Consultant acknowledges and agrees that Myovant will have no adequate remedy at law and would be irreparably harmed, if Consultant actually breaches or threatens to breach any of the provisions of Sections 5, and/or 6hereof.  Consultant agrees that Myovant shall be entitled to equitable and/or injunctive relief to prevent any actual breach or contemplated breach of Sections 5, and/or 6 hereof, and to specific performance of each of the terms of such Section in addition to any other legal or equitable remedies that Myovant may have.  Consultant further agrees that it shall not, in any equity proceeding relating to the enforcement of the terms of Sections 5, 6, 7 and/or 8 hereof, raise the defense that Myovant has an adequate remedy at law.       

7.2.Nothing contained in this Agreement shall limit, abridge, or modify the rights of Myovant under applicable trade secret, trademark, copyright, or patent law or under the laws of unfair competition.

7.3.The terms and provisions of Sections 5, 6, and/or 7 hereof are intended to be separate and divisible provisions and if, for any reason, any one or more of them is held to be invalid or unenforceable, neither the validity nor the enforceability of any other provision of this Agreement shall thereby be affected.  It is the intention of the parties to this Agreement that the potential restrictions on Consultant’s conduct are reasonable in both duration and geographic scope and in all other respects.  If for any reason any court of competent jurisdiction shall find any provisions of Sections 5, 6, and/or 7 unreasonable in duration or geographic scope or otherwise, the restrictions and prohibitions contained therein shall be effective to the fullest extent allowed under applicable law in such jurisdiction.  

8.Notices.

All notices, requests, consents, and other communications hereunder to any party shall be deemed to be sufficient if contained in a written instrument delivered in person (including delivery by overnight or express courier) or duly sent by certified mail, return receipt requested, proper postage prepaid, addressed to such party at the address set forth below or such other addresses as may hereafter be designated in writing by the addressee to the addressor listing all parties:

						
	Myovant:	Myovant Sciences GmbH
		c/o Myovant Sciences, Inc.
		2000 Sierra Point Parkway
		9th Floor 
		Brisbane, CA 94005
		Attn: Legal Department
		
	Consultant:	Sumitovant Biopharma, Inc.
		151 W. 42nd Street, 15th Floor
		New York, NY 10036
		Attn: Legal Department

All such notices, advices, and communications shall be deemed to have been received (a) in the case of personal delivery, on the date of actual personal receipt, and (b) in the case of mailing, on the third day after the posting by certified mail, return receipt requested.

9.Binding Agreement.

The rights and obligations of Myovant under this Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of Myovant.  This Agreement is a personal service agreement and may not be assigned in whole or in part by Consultant. 

10.Severable Provisions.

The provisions of this Agreement are severable and if any one or more provisions may be determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions, and any partial enforceable provision to the extent enforceable in any jurisdiction, shall nevertheless be binding and enforceable.

11.Waiver.

The waiver by one party of a breach of any provision of this Agreement by the other party shall not operate or be construed as a waiver of any subsequent breach of the same or any other provision by the other party.

12.Entire Agreement.

This Agreement constitutes the entire agreement of the parties hereto with respect to the engagement of Consultant by Myovant and supersedes all prior agreements, understandings, discussions, negotiations and undertakings, whether written or oral, between the parties with respect thereto and may not be changed orally, but only by an agreement in writing signed by the party against whom the enforcement of any waiver, change, modification, extension, or discharge is sought.

13.Counterparts.

This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all which together shall constitute one and the same instrument.   Signatures to this Agreement transmitted by facsimile, by electronic mail in “portable document format” (“.pdf”), or by any other electronic means which preserves the original graphic and pictorial appearance of the Agreement, shall have the same effect as physical delivery of the paper document bearing the original signature. 

14.Applicable Law.

This Agreement shall be governed by and construed in accordance with the laws of the State of New York without regard to its conflict of laws principles.  For all matters relating to or arising directly or indirectly from this Agreement in connection with any legal action, lawsuit, arbitration, mediation, or other legal or quasi legal proceeding, the parties hereby irrevocably consent and submit to the sole exclusive jurisdiction of the United States District Court for the Southern District of New York and any state court in the State of New York that is located in the county of New York (and the appropriate appellate courts of any of the foregoing).

15.Reporting.

It is understood by Consultant that if required by applicable law, rule or regulation, Myovant will report all payments and may be required to report other value transferred to Consultant under this Agreement.  Consultant understands that information about payments or other value transferred to Consultant may be made publicly available.  The obligations of this section shall survive the expiration or earlier termination of this Agreement.

16.Dispute Resolution.

Any dispute, claim or controversy arising out of or in connection with this Agreement, including any dispute regarding its existence, validity or termination (the “Dispute”), except to the extent that Myovant is seeking injunctive relief pursuant to Sections 5, 6, and/or 7 hereunder (which are governed by Section 14), shall be finally resolved through arbitration under the Commercial Arbitration Rules of the American Arbitration Association in force as of the date of this Agreement (the “Rules”).  The Dispute shall be resolved by a sole arbitrator appointed in accordance with the Rules. The place of arbitration shall be New York, New York.  The arbitration shall be conducted in the English language.  The award issued by the sole arbitrator shall be final and binding upon the parties and shall not be subject to appeal.

17.Captions.

The captions of this Agreement are not part of the provisions hereof and shall have no force or effect.

Signature Page to Follow

IN WITNESS WHEREOF, the duly authorized representatives of the parties hereto have caused this Agreement to be duly executed as of the date set forth.
															
	Myovant Sciences GmbH (“Myovant”)			Sumitovant Biopharma, Inc. (“Consultant”)	
					
	By:	/s/ Elke Hunsche		By:	/s/ Tara Soni
	Name:	Elke Hunsche		Name:	Tara Soni
	Title:	VP, Global Market Access & HEOR		Title:	Head of Legal

EXHIBIT A
Description of Consultant’s Services

•Project Name or Services Reference: Adele Gulfo, Interim Chief Commercial Officer for Myovant.
•Objective: Support Myovant in commercial planning, commercial launch activities and implementation.
•Scope of Work: Adele Gulfo to serve as Myovant’s interim Chief Commercial Officer with all associated responsibilities of this role provided that Myovant shall remain responsible for all administrative duties related to this role, including but not limited to, annual performance review of team members, training programs, replacement candidate search and so forth. The primary focus of this role relates to commercial launch preparation and implementation.
•Anticipated Timeframe to Completion:  Until permanent Chief Commercial Officer has been hired and onboarded by Myovant.  
•Deliverable(s): to be mutually agreed in writing based on individual projects. 
•Contact information:
Individual Consultant’s name
Adele Gulfo
151 W 42nd Street, 15th Floor, New York NY 10036
Email: [***]

Myovant contact
Lynn Seely
2000 Sierra Point Parkway, 9th Floor
Brisbane, CA 94005 USA
Email: [***]Exhibit 10.1

 

Execution Version

 

FIRST AMENDMENT TO

AMENDED AND RESTATED CREDIT AND GUARANTY
AGREEMENT

 

This
FIRST Amendment TO amended and restated CREDIT AND GUARANTY AGREEMENT (this “Amendment”), dated August
7, 2020, is entered into by and among Black Knight InfoServ, LLC, a Delaware limited liability company (the “Borrower”),
Black Knight Financial Services, LLC, a Delaware limited liability company (“Holdings”), the Lenders party hereto
(collectively constituting the Required Lenders) and JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the
“Administrative Agent”). Capitalized terms used herein shall have the meanings given to them in the Amended
Credit Agreement (as defined below) unless otherwise specified.

 

Recitals

 

WHEREAS, the Borrower,
Holdings, the Subsidiaries of the Borrower from time to time party thereto, the Lenders from time to time party thereto and the
Administrative Agent are parties to that certain Amended and Restated Credit and Guaranty Agreement, dated as of April 30, 2018
(as amended, restated, amended and restated, extended, supplemented or otherwise modified from time to time prior to the date hereof,
the “Credit Agreement” and as further amended by this Amendment, the “Amended Credit Agreement”).

 

WHEREAS, pursuant to
Section 11.01 of the Credit Agreement, the Borrower has requested certain amendments be made to the Credit Agreement and the Lenders
party hereto (collectively constituting the Required Lenders) have agreed to amend the Credit Agreement pursuant to the terms and
conditions set forth herein and therein.

 

NOW, THEREFORE, in consideration
of the premises and of the mutual covenants and agreements herein contained, it is agreed as follows:

 

1.                  
Amendments to Credit Agreement. Effective as of the First Amendment Effective
Date (defined below), the Credit Agreement is amended as follows:

 

(a)               
Section 1.01 of the Credit Agreement is hereby amended by inserting in the appropriate
alphabetical order the following new definitions: 

 

““BHC Act Affiliate” of a
party means an “affiliate” (as such term is defined under, and interpreted in accordance with, 12 U.S.C. 1841(k)) of
such party.

 

“Covered Entity” means any of the
following”

 

(i)            a “covered
entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b);

 

(ii)           a “covered
bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or

 

(iii)          a “covered
FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b).

 

“Covered
Party” has the meaning specified in Section 11.24.

 

    

     

    

 

“Default
Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§
252.81, 47.2 or 382.1, as applicable.

 

“QFC”
has the meaning assigned to the term “qualified financial contract” in, and shall be interpreted in accordance with,
12 U.S.C. 5390(c)(8)(D).

 

“QFC
Credit Support” has the meaning assigned to it in Section 11.24.

 

“Sapphire
Acquisition” means the acquisition, directly or indirectly, by the Borrower of all of the issued and outstanding equity
of each Sapphire Target pursuant to the terms of the Sapphire Acquisition Agreement.

 

“Sapphire
Acquisition Agreement” means that certain Equity Purchase Agreement, dated as of July 26, 2020, entered into by and among
Parent, GTCR Fund XI/C LP, a Delaware limited partnership, Sapphire Blocker, GTCR/OB Splitter LP, a Delaware limited partnership,
Sapphire Company, and OB Holdings I, LLC, a Delaware limited liability company, in its capacity as the Seller Representative.

 

“Sapphire
Blocker” means GTCR/OB Blocker Corp., a Delaware corporation.

 

“Sapphire
Company” means OB Acquisition, LLC, a Delaware limited liability company.

 

“Sapphire
Senior Unsecured Notes” means any debt securities issued by the Borrower in a public offering registered under the Securities
Act, or in an offering exempt from (or not subject to) the registration requirements of the Securities Act, in an aggregate principal
amount not to exceed the lesser of (i) $1,000,000,000 and (ii) the aggregate principal amount actually issued, (x) the proceeds
of which are to be applied directly or indirectly to finance the Sapphire Acquisition, including the repayment of indebtedness
as contemplated by the Sapphire Acquisition Agreement, payment of all or a portion of the purchase price and payment of the fees,
costs and other expenses in respect of the foregoing and (y) the terms of which may include a special mandatory redemption (a “SMR
Redemption”) of such debt securities in the event that the Sapphire Acquisition is not completed by a date determined
in or pursuant to the terms and conditions of such debt securities at a redemption price equal to 100% of the principal amount
thereof, plus accrued and unpaid interest.

 

“Sapphire
Notes SMR Escrow” means the deposit by the Borrower of the proceeds of the Sapphire Senior Unsecured Notes, together
with an amount necessary to finance any customary prepayment of interest, into escrow pending consummation of the Sapphire Acquisition
or the requirement to effect an SMR Redemption (as defined above) pursuant to the terms of the Sapphire Senior Unsecured Notes.

 

“Sapphire
Target” means, collectively, Sapphire Company and Sapphire Blocker.”

 

“Supported
QFC” has the meaning assigned to it in Section 11.24.

 

“U.S.
Special Resolution Regime” has the meaning specified in Section 11.24.”

 

    -2-

     

    

 

(b)               
 The definition of “Disqualified Equity Interests” in Section 1.01 of
the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

“Disqualified
Equity Interests” means any Equity Interest which, by its terms (or by the terms of any security or other Equity Interests
into which it is convertible or for which it is exchangeable), or upon the happening of any event or condition (a) matures or is
mandatorily redeemable, pursuant to a sinking fund obligation or otherwise, in each case, other than (i) for Qualified Equity Interests
or (ii) as a result of a “change of control”
or “asset sale”, (b) is redeemable at the option of the holder thereof, in whole or in part, other than (i) for Qualified
Equity Interests or (ii) as a result of a “change
of control” or “asset sale”, (c) provides for the scheduled payments of dividends in cash, or (d) is or becomes
convertible into or exchangeable for Indebtedness or any other Equity Interests that would constitute Disqualified Equity Interests,
in each case, prior to the date that is 91 days after the Latest Maturity Date; provided, that (x) for purposes of clause
(a) and (b) above, any Equity Interests that would not constitute Disqualified Equity Interests but for provisions thereof giving
holders thereof (or the holders of any security into or for which such Equity Interests
are convertible, exchangeable or exercisable) the right to require the issuer thereof to
redeem such Equity Interests upon the occurrence of a “change of control” or “asset sale” occurring prior
to the date that is 91 days after the Latest Maturity Date shall not constitute Disqualified Equity Interests if the terms of such
Equity Interests provide that the issuer thereof will not redeem any such Equity Interest pursuant to such provisions prior to
the Termination Date and (y) for purposes of clause (a) through (d) above, it is understood and agreed that if any such maturity,
redemption conversion, exchange, repurchase obligation or scheduled payment is in part, only such part coming into effect prior
to the date that is 91 days following the Latest Maturity Date (determined at the time such Equity Interest is issued) shall constitute
Disqualified Equity Interests.

 

(c)               
The definition of “Excluded Assets” in Section 1.01 of the Credit Agreement
is hereby amended by deleting the word “and” at the end of clause (xiii) thereof, inserting the word “and”
at the end of clause (xiv) thereof and inserting the following clause (xv):

 

“(xv)     cash
on deposit in respect of the Sapphire Notes SMR Escrow.”

 

(d)               
The definition of “Excluded Subsidiary” in Section 1.01 of the Credit
Agreement is hereby amended by amending and restating clause (b) thereof to read as follows:

 

“(b)      any
(i) non-wholly owned Subsidiary that is prohibited by any Organization Document or shareholder agreement (including a requirement
to obtain third-party consent) existing on the Closing Date (or, in the case of any Subsidiary acquired or which becomes non-wholly
owned after the Closing Date, any Organization Document or shareholder agreement in existence at such time) and (ii) any direct
or indirect Subsidiary of any such non-wholly owned Subsidiary that is an Excluded Subsidiary as a result of the foregoing clause
(i),”

 

(e)               
Section 7.01 of the Credit Agreement is hereby amended by deleting the word “and”
at the end of clause (aa) thereof, inserting the word “and” at the end of clause (bb) thereof and inserting the following
clause (cc):

 

    -3-

     

    

 

“(cc)     the
Sapphire Notes SMR Escrow and any Lien on amounts on deposit in the Sapphire Notes SMR Escrow for the benefit of the holders of
the Sapphire Senior Unsecured Notes and/or any trustee or agent in respect thereof.”

 

(f)                
Section 7.02 of the Credit Agreement is hereby amended by deleting the word “and”
at the end of clause (w) thereof, inserting the following clauses (y) and (z) thereafter:

 

“(y)      the
Sapphire Acquisition; and

 

(z)       Investments
made in joint ventures as required by, or made pursuant to, customary buy/sell arrangements between the joint venture parties set
forth in joint venture agreements and similar binding arrangements in each case entered into in the ordinary course of business.”

 

(g)               
Section 7.03(h) of the Credit Agreement is hereby amended by inserting the following
parenthetical to clause (ii)(2) of the proviso thereto after the words “shall be subject to any mandatory redemption, repurchase,
repayment or sinking fund obligation”: “(other than customary provisions as a result of a “change of control”
or “asset sale”)”,

 

(h)               
Section 7.03(z)(ii) of the Credit Agreement is hereby amended by inserting the following
parenthetical after the words “shall be subject to any mandatory redemption, repurchase, repayment or sinking fund obligation”:
“(other than customary provisions as a result of a “change of control” or “asset sale”)”, and

 

(i)                
Section 7.03 of the Credit Agreement is hereby amended by deleting the word “and”
at the end of clause (bb) thereof, inserting the word “and” at the end of clause (cc) thereof and inserting the following
clause (dd):

 

“(dd)     the
Sapphire Senior Unsecured Notes.”

 

(j)                
The Credit Agreement is hereby amended by adding a Section 11.24 as follows:

 

“Acknowledgement Regarding Any Supported
QFCs. To the extent that the Loan Documents provide support, through a guarantee or otherwise, for Swap Contracts or any other
agreement or instrument that is a QFC (such support “QFC Credit Support” and each such QFC a “Supported
QFC”), the parties acknowledge and agree as follows with respect to the resolution power of the Federal Deposit Insurance
Corporation under the Federal Deposit Insurance Act and Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act
(together with the regulations promulgated thereunder, the “U.S. Special Resolution Regimes”) in respect of
such Supported QFC and QFC Credit Support (with the provisions below applicable notwithstanding that the Loan Documents and any
Supported QFC may in fact be stated to be governed by the laws of the State of New York and/or of the United States or any other
state of the United States):

 

In the event a Covered Entity that is party to a
Supported QFC (each, a “Covered Party”) becomes subject to a proceeding under a U.S. Special Resolution
Regime, the transfer of such Supported QFC and the benefit of such QFC Credit Support (and any interest and obligation in or
under such Supported QFC and such QFC Credit Support, and any rights in property securing such Supported QFC or such QFC
Credit Support) from such Covered Party will be effective to the same extent as the transfer would be effective under the
U.S. Special Resolution Regime if the Supported QFC and such QFC Credit Support (and any such interest, obligation and rights
in property) were governed by the laws of the United States or a state of the United States. In the event a Covered Party or
a BHC Act Affiliate of a Covered Party becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights
under the Loan Documents that might otherwise apply to such Supported QFC or any QFC Credit Support that may be exercised
against such Covered Party are permitted to be exercised to no greater extent than such Default Rights could be exercised
under the U.S. Special Resolution Regime if the Supported QFC and the Loan Documents were governed by the laws of the United
States or a state of the United States. Without limitation of the foregoing, it is understood and agreed that rights and
remedies of the parties with respect to a Defaulting Lender shall in no event affect the rights of any Covered Party with
respect to a Supported QFC or any QFC Credit Support.”

 

    -4-

     

    

 

2.                  
Conditions of Effectiveness. The effectiveness of this Amendment are subject
to the satisfaction (or waiver) of the following conditions (the date of satisfaction of such conditions being referred to herein
as the “First Amendment Effective Date”):

 

(a)               
this Amendment shall have been duly executed by the Borrower, the Required Lenders and the Administrative Agent (which
may include a copy transmitted by facsimile or other electronic method), and delivered to the Administrative Agent; and

 

(b)               
all fees and expenses required to be paid by (or on behalf of) the Borrower to the Administrative Agent (including
pursuant to Section 11.04 of the Credit Agreement) shall have been paid in full in cash.

 

3.                  
Representations and Warranties. The Borrower hereby represents and warrants
to the Administrative Agent and the Lenders party hereto as of the First Amendment Effective Date that:

 

(a)               
this Amendment has been duly executed and delivered by the Borrower and the Amended
Credit Agreement constitutes a legal, valid and binding obligation of the Borrower, enforceable against the Borrower in accordance
with its terms, except as such enforceability may be limited by bankruptcy insolvency, reorganization, receivership, moratorium
or other Laws affecting creditors’ rights generally and by general principles of equity; and

 

(b)               
the representations and warranties contained in Article 5 of the Amended Credit Agreement
and the other Loan Documents are correct in all material respects (except that such materiality qualifier shall not be applicable
to any representations and warranties that already are qualified or modified by materiality in the text thereof) on and as of the
First Amendment Effective Date as though made on and as of such date (except to the extent that such representations and warranties
relate solely to an earlier date, in which case such representations and warranties shall be true and correct in all material respects
(except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified
or modified by materiality in the text thereof) as of such earlier date). 

 

4.                  
References. All references in the Credit Agreement to “this Agreement”
“hereunder”, “hereof”, “herein” or words of like import referring to the Credit Agreement shall
be deemed to refer to the Amended Credit Agreement; and any and all references in the Loan Documents to the Credit Agreement shall
be deemed to refer to the Amended Credit Agreement. The Borrower acknowledges and agrees that, on and after the First Amendment
Effective Date, this Amendment shall constitute a Loan Document for all purposes of the Amended Credit Agreement.

 

5.                   No
Waiver. The execution of this Amendment and the acceptance of all other agreements and instruments related hereto shall
not be deemed to be a waiver of any Default or Event of Default under the Credit Agreement or a waiver of any breach, default
or event of default under any Loan Document, whether or not known to Administrative Agent and whether or not existing on the
date of this Amendment. Except as specifically amended herein or contemplated hereby, all Loan Documents shall continue to be
in full force and effect and are hereby in all respects ratified and confirmed. The execution, delivery and effectiveness of
this Amendment shall not operate as a waiver of any right, power or remedy of any Lender or the Administrative Agent under
any of the Loan Documents, nor constitute a waiver of any provision of the Loan Documents or in any way limit, impair or
otherwise affect the rights and remedies of the Lenders or the Administrative Agent under the Loan Documents. Nothing
herein shall be deemed to entitle the Borrower to a further consent to, or a further waiver, amendment, modification or other
change of, any of the terms, conditions, obligations, covenants or agreements contained in the Amended Credit Agreement or
any other Loan Document in similar or different circumstances.

 

    -5-

     

    

 

6.                  
Counterparts; Severability. This Amendment may be executed in any number of counterparts, each of which, when
so executed and delivered, shall be deemed an original and all of which counterparts, when taken together, shall constitute one
and the same instrument. Delivery of an executed counterpart of this Amendment by telefacsimile or other electronic method of transmission
(including deliveries by telecopy, emailed pdf. or any other electronic means that reproduces an
image of an actual executed signature page) shall be equally as effective as delivery of an original executed counterpart
of this Amendment; provided that nothing herein shall require the Administrative Agent to accept electronic signatures in any form
or format without its prior consent and pursuant to procedures approved by it; provided, further, without limiting the foregoing,
to the extent the Administrative Agent has agreed to accept any electronic signature, the Administrative Agent and each of the
Lenders shall be entitled to rely on such electronic signature purportedly given by or on behalf of the Borrower without further
verification thereof and without any obligation to review the appearance or form of any such electronic signature and upon the
request of the Administrative Agent or any Lender, any electronic signature shall be promptly followed by a manually executed counterpart.
If any provision of this Amendment is held to be illegal, invalid or unenforceable, the legality, validity and enforceability of
the remaining provisions of this Amendment shall not be affected or impaired thereby. The invalidity of a provision in a particular
jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

 

7.                  
Governing Law. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE
WITH, THE LAWS OF THE STATE OF NEW YORK. THE PROVISIONS OF SECTIONS 11.16(B) AND 11.17 OF THE AMENDED CREDIT AGREEMENT SHALL APPLY
TO THIS AMENDMENT TO THE SAME EXTENT AS IF FULLY SET FORTH HEREIN. 

 

8.                  
Indemnification. The Borrower hereby confirms that the indemnification provisions
set forth in Section 11.05 of the Amended Credit Agreement shall apply to this Amendment and the transactions contemplated hereby.

 

9.                  
Acknowledgement and Reaffirmation of Guarantors. Holdings and the Borrower acknowledge and agree on behalf
of the Guarantors that this Amendment does not operate to reduce or discharge the Guarantors’ obligations under the Amended
Credit Agreement and/or the Loan Documents. Holdings and the Borrower on behalf of each Guarantor hereby ratify and confirms such
Guarantors’ obligations under the Loan Documents including, without limitation, the Guarantors’ guarantee of the Obligations
and grant of the security interest in the Collateral (as defined in the Collateral Documents) to secure the Obligations.

 

[Signature Pages Follow]

 

    -6-

     

    

 

IN WITNESS WHEREOF, the
parties hereto have caused this Amendment to be duly executed as of the date first above written.

 

 

	 	BLACK KNIGHT INFOSERV, LLC, as the Borrower
	 	 
	 	By:	/s/ Michael L. Gravelle

		Name:	Michael L. Gravelle
		Title:	Executive Vice President, General Counsel and 

Corporate Secretary

 

	 	 
	 	BLACK KNIGHT FINANCIAL SERVICES, LLC,
	 	as Holdings
	 	 
	 	By:	/s/ Michael L. Gravelle

		Name:	Michael L. Gravelle
		Title:	Executive Vice President, General Counsel and 

Corporate Secretary

 

[Signature Page to First Amendment to Amended and Restated Credit and Guaranty Agreement]

 

    

     

    

 

	 	JPMORGAN CHASE BANK, N.A.,
	 	as Administrative Agent and Lender
	 	 
	 	By:	/s/ Inderjeet Aneja
	 	 	Name: Inderjeet Aneja
	 	 	Title: Executive Director

 

[Signature Page to First Amendment to Amended and Restated Credit and Guaranty Agreement]

 

    

     

    

 

 

 

	 	Bank of America, N.A.,
	 	As a Revolving Credit Lender and Term Lender
	 	 	 
		By:	/s/ Ravi
                                         Patel
	 	 	Name: Ravi Patel
	 	 	Title: Vice President

 

[Signature Page to First Amendment to Amended and Restated Credit and Guaranty Agreement]

 

    

     

    

 

	 	PNC Bank
National Association, as Lender
	 	 	 
	 	By:	/s/ James Cullen
	 	 	Name: James Cullen
	 	 	Title: Senior Vice President

 

[Signature Page to
First Amendment to Amended and Restated Credit and Guaranty Agreement]

 

    

     

    

 

	 	Truist Bank,
as successor by merger to SunTrust Bank,
	 	as Lender
	 	 	 
	 	By:	/s/ David Bennett
	 	 	Name: David Bennett
	 	 	Title: Director

 

[Signature Page to
First Amendment to Amended and Restated Credit and Guaranty Agreement]

 

    

     

    

 

	 	U.S. Bank
National Association, as Lender
	 	 
	 	By:	/s/ James F. Cooper
	 	 	Name: James F. Cooper
	 	 	Title: Sr. Vice President

 

[Signature Page to
First Amendment to Amended and Restated Credit and Guaranty Agreement]

 

    

     

    

 

	 	Wells Fargo
Bank, N.A.,
	 	as a Revolving
Credit Lender and Term Loan Lender
	 	 
	 	By:	/s/ Nathan Paouncic
	 	 	Name: Nathan Paouncic
	 	 	Title: Vice President

 

[Signature Page to
First Amendment to Amended and Restated Credit and Guaranty Agreement]

 

    

     

    

 

 

	 	Bank of Montreal,
	 	as a Revolving
Credit Lender and Term Loan Lender
	 	 
	 	By:	/s/ Sean Ball
	 	 	Name: Sean Ball
	 	 	Title: Managing Director

 

[Signature Page to First Amendment to Amended and Restated Credit and Guaranty Agreement]

 

    

     

    

 

	 	Capital One,
National Association,
	 	as a Revolving
Credit Lender and Term Loan Lender
	 	 
	 	By:	/s/ Nirmal Bivek
	 	 	Name: Nirmal Bivek
	 	 	Title: Duly Authorized Signatory

 

[Signature Page to First Amendment to Amended and Restated Credit and Guaranty Agreement]

 

    

     

    

 

 

	 	Citizens
Bank, N.A., as Lender
	 	 
	 	By:	/s/ Jason Hembree
	 	 	Name: Jason Hembree
	 	 	Title: Vice President

 

[Signature Page to
First Amendment to Amended and Restated Credit and Guaranty Agreement]

 

    

     

    

 

	 	Fifth Third
Bank, National Association, as Lender
	 	 
	 	By:	/s/ Eric Oberfield
	 	 	Name: Eric Oberfield
	 	 	Title: Director

 

[Signature Page to
First Amendment to Amended and Restated Credit and Guaranty Agreement]

 

    

     

    

 

	 	Mizuho Bank,
Ltd.,
	 	as a Revolving
Credit Lender and Term Loan Lender
	 	 
	 	By:	/s/ Tracy Rahn
	 	 	Name: Tracy Rahn
	 	 	Title: Executive Director

 

[Signature Page to
First Amendment to Amended and Restated Credit and Guaranty Agreement]

 

    

     

    

 

	 	Regions Bank,
as Lender
	 	 
	 	By:	/s/ Tyler Tirpak
	 	 	Name: Tyler Tirpak
	 	 	Title: Associate

 

[Signature Page to
First Amendment to Amended and Restated Credit and Guaranty Agreement]

 

    

     

    

 

	 	Truist Bank,
formerly known as Branch Banking and Trust Company, as Lender
	 	 
	 	By:	/s/ David Bennett
	 	 	Name: David Bennett
	 	 	Title: Director

 

[Signature Page to
First Amendment to Amended and Restated Credit and Guaranty Agreement]

 

    

     

    

			

 

	 	Goldman Sachs
Bank USA,
	 	as a Revolving
Credit Lender
	 	 
	 	By:	/s/ David K. Gaskell
	 	 	Name: David K. Gaskell
	 	 	Title: Authorized Signer

 

[Signature Page to
First Amendment to Amended and Restated Credit and Guaranty Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}]]